Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 25;17(1):371.
doi: 10.1186/s12885-017-3370-x.

Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience

Branisav Oluic  1 , Ivan Paunovic  2   3 , Zlatibor Loncar  4   3 , Vladimir Djukic  4   3 , Aleksandar Diklic  2   3 , Milan Jovanovic  2 , Zeljko Garabinovic  5 , Nikola Slijepcevic  2 , Branislav Rovcanin  2 , Dusan Micic  4 , Aleksandar Filipovic  6 , Vladan Zivaljevic  2   3
Affiliations

Survival and prognostic factors for survival, cancer specific survival and disease free interval in 239 patients with Hurthle cell carcinoma: a single center experience

Branisav Oluic et al. BMC Cancer. .

Abstract

Background: Hurthle cell carcinoma makes up 3 to 5% of all thyroid cancers and is considered to be a true rarity. The aim of our study was to analyze clinical characteristics and survival rates of patients with Hurthle cell carcinoma.

Methods: Clinical data regarding basic demographic characteristics, tumor grade, type of surgical treatment and vital status were collected. Methods of descriptive statistics and Kaplan-Meier survival curves were used for statistical analysis. Cox proportional hazards regression was used to identify independent predictors.

Results: During the period from 1995 to 2014, 239 patients with Hurthle cell carcinoma were treated at our Institution. The average age of the patients was 54.3, with female to male ratio of 3.6:1 and average tumor size was 41.8 mm. The overall recurrence rate was 12.1%, with average time for relapse of 90.74 months and average time without any signs of the disease of 222.4 months. Overall 5-year, 10-year and 20-year survival rates were 89.4%, 77.2%, 61.9% respectively. The 5-year, 10-year and 20-year cancer specific survival rates were 94.6%, 92.5%, 87.4%, respectively. When disease free interval was observed, 5-year, 10-year and 20-year rates were 91.1%, 86.2%, 68.5%, respectively. The affection of both thyroid lobes and the need for reoperation due to local relapse were unfavorable independent prognostic factors, while total thyroidectomy as primary procedure was favorable predictive factor for cancer specific survival.

Conclusion: Hurthle cell carcinoma is a rare tumor with an encouraging prognosis and after adequate surgical treatment recurrences are rare.

Keywords: Cancer specific survival; Disease free interval; Hurthle cell carcinoma; Survival; Thyroid gland.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hurthle cell carcinoma: a) without capsular or vascular invasion, b) capsular invasion, c) vascular invasion
Fig. 2
Fig. 2
Kaplan-Meier overall survival curve
Fig. 3
Fig. 3
Kaplan-Meier cancer specific survival curve
Fig. 4
Fig. 4
Kaplan-Meier disease free interval curve
See this image and copyright information in PMC

References

    1. Nagar S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, Grogan RH. Hurthle cell carcinoma: an update on survival over the last 35 years. Surgery. 2013;154(6):1263–1271. doi: 10.1016/j.surg.2013.06.029. - DOI - PubMed
    1. Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer. 2013; 1;119(3):504–11. - PubMed
    1. Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, et al. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. J Clin Endocrinol Metab. 2013;98(5):E962–E972. doi: 10.1210/jc.2012-3539. - DOI - PMC - PubMed
    1. Bhattacharyya N. Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Arch Otolaryngol Head Neck Surg. 2003;129(2):207–210. doi: 10.1001/archotol.129.2.207. - DOI - PubMed
    1. Shaha AR. TNM classification of thyroid carcinoma. World J Surg. 2007;31(5):879–887. doi: 10.1007/s00268-006-0864-0. - DOI - PubMed